Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1096 to 1110 of 1422 results for social care

  1. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    In development [GID-TA10822] Expected publication date: TBC

  2. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued [GID-HST10007]

  3. Is contingency management effective in reducing alcohol consumption in people who misuse alcohol compared with standard care?

    reducing alcohol consumption in people who misuse alcohol compared with standard care? Any explanatory notes(if applicable) Why this is...

  4. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development [GID-TA10858] Expected publication date: TBC

  5. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

  6. Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.

  7. Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment (HTE6)

    Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies...

  8. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

  9. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued [GID-TA10697]

  10. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued [GID-TA10591]

  11. Lasmiditan for treating acute migraine [ID3759]

    Discontinued [GID-TA10807]

  12. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued [GID-TA10185]

  13. Is acupuncture effective in reducing alcohol consumption compared with standard care?

    acupuncture effective in reducing alcohol consumption compared with standard care? Any explanatory notes(if applicable) Why this is...

  14. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.